Amphastar Pharmaceuticals (AMPH) Income from Continuing Operations (2013 - 2026)
Amphastar Pharmaceuticals (AMPH) posted quarterly Income from Continuing Operations of 6420000.0 for Q1 2026, down 74.61% year-over-year from 25285000.0 in Q1 2025, and down 86.51% quarter-over-quarter from 47583000.0 in Q4 2025.
Amphastar Pharmaceuticals (AMPH) Income from Continuing Operations (2013 - 2026) Analysis & Trends
Amphastar Pharmaceuticals' Income from Continuing Operations history runs 14 years deep, the most recent figure standing at 6420000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 74.61% year-over-year to 6420000.0; the TTM figure through Mar 2026 stood at 102383000.0 (down 27.71% YoY), while the FY2025 annual figure was 121248000.0, down 24.26% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 6420000.0, down from 47583000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 49612000.0 in Q3 2023, with the low at 145250000.0 in Q4 2023.
- The 5-year median for Income from Continuing Operations is 26817000.0 (2023), against an average of 19878058.82.
- The sharpest annual moves came in 2022 and 2023: Income from Continuing Operations surged 530.36% in 2022, then sank 527.58% in 2023.
- Amphastar Pharmaceuticals' Income from Continuing Operations stood at 33970000.0 in 2022, then tumbled by 527.58% to 145250000.0 in 2023, then surged by 126.14% to 37964000.0 in 2024, then climbed by 25.34% to 47583000.0 in 2025, then tumbled by 86.51% to 6420000.0 in 2026.
- Business Quant data shows AMPH's Income from Continuing Operations at 6420000.0 in Q1 2026, 47583000.0 in Q4 2025, and 17350000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.07 Bn | 43.10 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.42 Bn | 39.76 Bn | 2.15 Bn | -576.00 Mn |
| 3 | Zoetis | 31.86 Bn | 30.18 Bn | 1.05 Bn | 866.00 Mn |
| 4 | Takeda Pharmaceutical | 28.77 Bn | 22.98 Bn | 5.10 Bn | 1.33 Bn |
| 5 | United Therapeutics | 22.29 Bn | 19.63 Bn | 683.80 Mn | 333.00 Mn |
| 6 | Viatris | 18.78 Bn | 17.89 Bn | 1.46 Bn | -118.80 Mn |
| 7 | Neurocrine Biosciences | 15.66 Bn | 15.27 Bn | 935.80 Mn | 144.40 Mn |
| 8 | Elanco Animal Health | 11.91 Bn | 11.38 Bn | 798.00 Mn | 54.00 Mn |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 10.00 Bn | - | - |
| 10 | Amphastar Pharmaceuticals | 934.42 Mn | 644.30 Mn | 93.47 Mn | 30.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 30.35 Mn |
| Mar 31, 2026 | 6.42 Mn |
| Dec 31, 2025 | 47.58 Mn |
| Sep 30, 2025 | 17.35 Mn |
| Jun 30, 2025 | 31.03 Mn |
| Mar 31, 2025 | 25.29 Mn |
| Dec 31, 2024 | 37.96 Mn |
| Sep 30, 2024 | 40.43 Mn |
| Jun 30, 2024 | 37.95 Mn |
| Mar 31, 2024 | 43.75 Mn |
| Dec 31, 2023 | -145.25 Mn |
| Sep 30, 2023 | 49.61 Mn |
| Jun 30, 2023 | 26.43 Mn |
| Mar 31, 2023 | 26.82 Mn |
| Dec 31, 2022 | 33.97 Mn |
| Sep 30, 2022 | 16.04 Mn |
| Jun 30, 2022 | 17.60 Mn |
| Mar 31, 2022 | 24.96 Mn |
| Dec 31, 2021 | 19.97 Mn |
| Sep 30, 2021 | 30.96 Mn |